Precision Business Insights


Early Stage Molecular Diagnostics Market

: Global Market Estimation, Dynamics, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025

Global Early Stage Molecular Diagnostics Market: By Product (Reagents and consumables, Software and services, Instruments), By Technology (PCR, In Situ Hybridization, Chips and microarrays, Mass spectrometry, Sequencing, Isothermal Amplification), By Application (Cancer, Infectious disease, Nephrological diseases, Immune system disorders, Gastrointestinal disorders, Neurological disorders, Others), End User (Hospitals, Diagnostic centres, Point of care testing, R and D centres) By Geography


Early Stage Molecular Diagnostics Market


Market Outline: Early Stage Molecular Diagnostics Market

Early Stage Molecular Diagnostics is a strategy for breaking down and distinguishing the organic markers in the genome and proteome to recognize quality articulation by applying sub-atomic science. Sub-atomic diagnostics are utilized to analyze sickness and hazard included. Sub-atomic Diagnostics chooses the treatments are reasonable for singular patients. The new propelled advances has qualified the instruments in giving precise outcomes. This capacity of the symptomatic apparatus brought about expanded rate of acknowledgment of the sub-atomic diagnostics. The idea of customized prescription has risen out of atomic diagnostics. Late diagnosis of constant illnesses is the greatest block to positive patient results and has major financial ramifications. How about we take the case of tumor, a standout amongst the most heterogeneous illnesses with numerous sub-types. The WHO evaluates that just about one of every six deaths internationally are caused by tumor and in low and center salary nations, malignancy cancer deaths exceed deaths caused by all major irresistible illnesses joined, including TB, jungle fever and HIV/AIDS. It is no fortuitous event that right around 66% of growth passings happen in low and center wage nations where late stage clinical introduction and deferrals in mind just fuel the rates of recuperation, compelling patients into an endless loop of weakness and financial wretchedness. The WHO has perceived the significance of early illness location and has advanced a two-advance process (see figure beneath) which incorporates screening (recognizable proof of asymptomatic infection in an evidently solid target populace) and early finding (acknowledgment of symptomatic tumor in patients at a beginning time)


Market Dynamics: Early Stage Molecular Diagnostics Market 

Increasing expenditure on healthcare sector in emerging markets, huge demand for the advanced technological methods of testing methods for the diagnosis of the disease may propel the early stage molecular diagnostics market. Furthermore, rising adaptation of point care testing, rising incidences of lifestyle diseases which are chronic, increase in number of laboratories with developed infrastructure in developed countries are the few factors boosting the growth of the early stage molecular diagnostics market. However, unfavourable reimbursement policies in developing countries and strict regulatory framework are few factors that are restraining the growth of the early stage molecular diagnostics market.


Market Scope: Early Stage Molecular Diagnostics Market 

The Early Stage Molecular Diagnostics Market is classified on the basis of product, technology, application , end user, and geographical regions.


Based on Product, Global Market is segmented into

  • Reagents and consumables
  • Software and services
  • Instruments


Based on Application, Global Market is segmented into

  • Cancer
  • Infectious disease
  • Nephrological diseases
  • Immune system disorders
  • Gastrointestinal disorders
  • Neurological disorders
  • Others


Based on Technology, Global Market is segmented into

  • PCR
  • In Situ Hybridization
  • Chips and microarrays
  • Mass spectrometry
  • Sequencing
  • Isothermal Amplification


Based on End User, Global Market is segmented into

  • Hospitals
  • Diagnostic centres
  • Point of care testing
  • R and D centres




North America

  • US
  • Canada


  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe


  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Venezuela
  • Rest of Latin America

Middle East and Africa (MEA)

  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA


Market Summary:   

Key players are adopting various strategies like mergers and acquisitions to build their piece of the pie. For example, Hologic obtained Gen-Probe in July 2012 to extend the portfolio with center around tumor diagnostics. Players are additionally concentrating on growing their item portfolio. For example, Cepheid propelled GeneXpert Omni, the world’s most convenient atomic diagnostics framework in 2015.Increase in financing by governments and distinctive associations for clinical examinations in the sub-atomic analysis space is required to support the market development. These activities assume a fundamental part during the time spent new item improvement, for example, Accelerate Diagnostics got financing of USD 19.5 million distinct associations, for example, the Schuler Family Foundation, Oracle Institutional Partners, Oracle Partners, and others, for the advancement and offer of irresistible ailment IVD tests and apparatuses. Besides, in April 2014, Merck’s investment arm financed AdvanDx with USD 12 million for innovative work of pathogen screening for significant clinic procured diseases.


Regional Analysis:

Geographically Early Stage Molecular Diagnostics Market is segmented as Latin America, North America, Asia- Pacific, The Middle East & Africa and Europe. North America is the largest market with highest share in the early stage molecular diagnostics market, which is followed by the Europe owing easy accessibility for advanced technologies, presence of large pool of manufacturers in early stage molecular diagnostics market, increasing prevalence of chronic genetic and lifestyle diseases. Asia-Pacific early stage molecular diagnostics market is expected to show fastest growth rate and also will emerge as area with maximum growth potential owing to the improving infrastructure of healthcare sector and growing economies in India and China.


Market participants: Early Stage Molecular Diagnostics Market 

Some of the players in Early Stage Molecular Diagnostics Market

  • Becton, Dickinson and Company (U.S.)
  • Abbott Laboratories (U.S.)
  • Danaher Corporation (U.S.)
  • Roche Diagnostics (Switzerland)
  • Siemens Healthineers (Germany)
  • Thermo Fisher Scientific, Inc. (U.S.)
  • Sysmex Corporation (Japan)
  • bioMérieux (France)
  • Bio-Rad Laboratories, Inc. (U.S.)
  • Qiagen N.V. (Germany)
  • Diasorin S.P.A. (Italy)
  • Ortho-Clinical Diagnostics, Inc. (U.S.),